In 2022, what new trends will there be in the development of domestic innovative drugs?

In recent years, China has attached great importance to pharmaceutical innovation, and has issued a series of planning policies such as the Outline of the National Innovation-Driven Development Strategy, the 13th Five-Year Plan for National Science and Technology Innovation, and the Guidelines for the Development of the Pharmaceutical Industry
.
It is worth noting that all of them put forward goals for the development of innovative drugs, and set up special projects to promote the research and development of new drugs
.
At present, the industry generally believes that with the help of many favorable policies, China will usher in a big window of drug innovation
.
Under such a trend, what new development trends will the domestic innovative drug industry have in 2022? In this regard, after sorting out the development status of domestic innovative drugs, the author believes that there will be three major trends in the development of domestic innovative drugs in 2022
.
What new trends will there be in the development of domestic innovative drugs? (Source: PharmaNet) In 2022, the launch of innovative drugs in China will accelerate.
With the help of policies and the efforts of major pharmaceutical companies, the number of domestic innovative drugs approved has been increasing in recent years
.
According to data, in 2021, the State Food and Drug Administration has approved 81 new drugs for the market, which is a new high compared with 48 new drugs in 2020
.
It is worth noting that in addition to the substantial increase in the number of approvals, there are also a variety of therapeutic areas.
The approved drugs mainly involve drugs for diseases such as tumors, autoimmune systems, viruses and infections
.
In addition, among the new drugs approved for marketing, in addition to biopharmaceuticals and chemical drugs, there are also many new traditional Chinese medicine drugs
.
From the above point of view, it is clear that China has ushered in a big window of drug innovation
.
Therefore, the author believes that in the future, driven by policies, superimposed on the science and technology innovation board, registration system, etc.
, the capital of innovative drugs will continue to swarm, and domestic innovative drugs will accelerate into the harvest period
.
Especially on December 30, 2021, 8 departments including the State Food and Drug Administration jointly issued the "14th Five-Year Plan for National Drug Safety and Promotion of High-Quality Development", which clarified that my country's drug safety and promotion of high-quality development during the "14th Five-Year Plan" period.
After the main development goals of quality development and 10 main tasks have been formulated, it is expected that more and more heavyweight innovative products will continue to emerge in the next few years..
Increased investment in R&D and differentiated innovation in the past two years.
Although the number of approved innovative drugs has increased rapidly, there are not many first-in-class new drugs approved in China; the varieties are mainly concentrated in anti-tumor Drugs, antiviral and anti-infectives, and pain relievers
.
According to data, there have been more than 60 clinical trials on VEGFR, PD-L1 and other targets in China
.
Among them, PD-1, which has been sought after by enterprises, has nearly 100 clinical trials
.
In this context, the industry expects that pharmaceutical companies will continue to increase investment in research and development in the new year in terms of researching new targets, new mechanisms, new indications, and new technologies
.
In fact, many pharmaceutical companies have begun to pay more and more attention to the homogenization of innovation, and are actively adjusting their development strategies
.
If a considerable number of innovative pharmaceutical companies are deploying their R&D pipelines based on "clinical value", it is reported that the world's first subcutaneous PD-L1 inhibitor KN035 (envolimab), which is about to be launched by Corning Jereh, is just on the dosage form.
The mode of administration has been optimized
.
The process of internationalization of domestic innovative drugs will continue to accelerate.
From the current point of view, with the steady progress of medical reform and the continuous expansion of centralized procurement, the domestic innovative drug industry is ushering in rapid development.
The number of new drugs approved and the proportion of clinical trial applications It is hitting new highs year by year
.
It is worth noting that, at the same time, more and more domestic innovative drugs and innovative drugs have also begun to accelerate overseas
.
Statistics show that in 2020, the number of Chinese medicines going overseas has reached 23
.
In 2021, the momentum is even more overwhelming.
The number of overseas authorized transactions of local pharmaceutical companies has exceeded 30, involving a large number of pharmaceutical companies such as BeiGene, Rongchang Bio, and Livzon Group
.
It is worth mentioning that, in addition to the continuous increase in the number of overseas drugs, the amount of a single transaction last year also reached a new high
.
It is reported that on August 8, 2021, Rongchang Biotech and Seattle Genetics reached a cooperation agreement to develop and commercialize its new ADC drug Vidicitumab, with a transaction value of up to US$2.
6 billion
.
It is expected in the industry that with the continuous improvement of innovation strength, the global market will become the development target of many domestic innovative companies, and a large number of pharmaceutical companies will continue to accelerate the process of going overseas
.
However, it should be noted that internationalization is not only the import and export of products, but the entire business direction of domestic pharmaceutical companies, including multi-faceted systematic engineering such as strategic positioning, product structure, and technical management.
International development also requires more serious research and analysis of market demands and rules, and steady progress
.